Welcome to our dedicated page for CEAPRO news (Ticker: CRPOF), a resource for investors and traders seeking the latest updates and insights on CEAPRO stock.
Ceapro Inc (CRPOF) is a Canadian biotechnology company specializing in the development of proprietary extraction technology for producing extracts and active ingredients from oats and other plant resources. The company supports the use of its extracts in cosmeceutical, nutraceutical, and therapeutic products for human and animal health. Ceapro leverages its expertise in natural product chemistry, microbiology, biochemistry, immunology, and process engineering to create active ingredients, biopharmaceuticals, and drug-delivery solutions. Visit Ceapro's website for more information.
Ceapro reported record sales of $17.2 million for FY 2021, a 14% increase from FY 2020's $15.1 million. The net profit surged to $2.84 million, up 53% from $1.86 million in 2020. R&D efforts are focused on avenanthramide pills for a Phase 1 study, with advancements in immune boosters and inhalable therapeutics underway. Despite challenges from the COVID-19 pandemic, the company achieved robust production levels and increased its profitability margins from 50% to 56%. Looking ahead, management anticipates sustained growth in cosmeceuticals and significant R&D investments.
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) announced a long-term agreement with Symrise AG for the distribution of its high-value active ingredients in the cosmetic market. The agreement provides Symrise exclusivity for several key international customers, ensuring minimum annual purchases from Ceapro. Although financial terms remain undisclosed, the partnership is expected to enhance Ceapro's cosmeceuticals business and broaden its customer base, reflecting confidence in Ceapro's product quality and potential for growth.
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) announced the appointment of Ronnie Miller, former President and CEO of Roche Canada, to its Board of Directors. With over 43 years of experience in the pharmaceutical industry, Miller aims to guide Ceapro in expanding its natural ingredient expertise into new therapeutic areas. His previous achievements include managing Roche Canada and advocating for healthcare advancements. Miller received options for 150,000 common shares, with a vesting schedule over three years. This strategic addition to the board is expected to enhance Ceapro's business growth and development.
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF), a biotechnology company, announced a live video webcast presentation scheduled for January 27, 2022, at 3:00 PM ET, during the Virtual Investor 2022 Top Picks Conference. CEO Gilles Gagnon will present the company's innovative extraction technologies for healthcare and cosmetics. The event will feature a presentation followed by a Q&A session where attendees can submit questions live or in advance. A replay of the webcast will be available on the company's website.
Ceapro (OTCQX: CRPOF) has announced receipt of up to $480,000 in funding from the National Research Council of Canada Industrial Research Assistance Program to enhance its Pressurized Gas eXpanded Technology (PGX) for pharmaceutical applications. This support will enable the design of a pharmaceutical-grade PGX processing unit aimed at producing yeast beta glucan, which is being studied as a potential treatment for lung diseases including those related to COVID-19. The project is expected to boost Ceapro's capacity for developing active pharmaceutical ingredients.
Ceapro reported a strong Q3 2021, achieving record sales of $4.52 million, a 30% increase from Q3 2020. Net profit surged by 356% to $875,000. The company is advancing R&D projects, including trials for oat beta glucan as a cholesterol reducer and yeast beta glucan for COVID-19 therapy. Production reached a record 70 MT, despite pandemic challenges. However, a beta glucan clinical trial did not meet primary endpoints, highlighting potential hurdles. Overall, Ceapro is poised for growth, focusing on innovation and expansion in the nutraceutical sector.
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) reported preliminary results from a clinical trial assessing the efficacy and safety of oat beta glucan for hyperlipidemia. The trial, involving 263 patients, aimed to compare three dosages of beta glucan against a placebo. While the primary endpoint related to LDL-C did not yield statistically significant results, some positive trends were noted in weight and body-mass index changes, albeit without statistical significance. The product meets market authorization requirements, indicating potential future benefits from continued research.
Ceapro (TSX-V: CZO; OTCQX: CRPOF) announced significant advancements in its collaboration with McMaster University, focusing on PGX-processed yeast beta-glucans (PGX-YBG) for treating fibrotic lung diseases and COVID-19. The research indicates that PGX-YBG can reprogram macrophages, addressing fibrosis by converting pro-fibrotic macrophages to anti-inflammatory types. Preliminary in vivo studies show potential in preventing lung fibrogenesis. Ceapro aims to optimize PGX-YBG delivery for future human trials, crucial for patients suffering from serious lung conditions.
Ceapro Inc. (OTCQX: CRPOF), a biotechnology company, will participate in a Virtual Investor Roundtable Event on November 17, 2021, at 11:00 AM ET. The event will feature a presentation by CEO Gilles Gagnon, followed by a moderated roundtable discussion and a Q&A session. Investors can submit questions live or in advance. A live video webcast will be available on the company's website, with a replay accessible for one year afterward. Ceapro specializes in developing active ingredients for healthcare and cosmetics from oats and other renewable resources.
Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) announced that its CEO, Gilles Gagnon, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. This virtual event will allow management to engage in one-on-one meetings with registered investors. A video webcast of the presentation will be available on-demand starting September 13, 2021, at 7:00 AM ET, and will be archived for 90 days. Ceapro specializes in developing active ingredients from plant resources for healthcare and cosmetic applications.
FAQ
What is the current stock price of CEAPRO (CRPOF)?
What is the market cap of CEAPRO (CRPOF)?
What is Ceapro Inc?
What products does Ceapro specialize in?
What expertise does Ceapro have?
Where can I get more information about Ceapro Inc?
